Clinical Trials in the USA / NCT05377996
Recruiting
Phase 1/2
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT05377996 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Triple Negative Breast CancerBreast CancerEndometrial CancerOvarian CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerAdenoid Cystic Carcinoma
Investigational drug(s) / intervention(s)
Emi-Le
Emi-Le: Emi-Le will be administered through a vein in your arm or port catheter (intravenously)
Study summary
A Study of Emi-Le in Participants with Solid Tumors
Eligibility
Inclusion Criteria:
* Recurrent or advanced solid tumor and has disease
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Participants in DES must have at least one measurable disease (target) lesion as defined by RECIST version 1.1.
* Tumor tissue, either archival or from a fresh tumor biopsy, available for testing or be willing to undergo a minimally invasive tumor biopsy to obtain tumor tissue for local testing, if not medically contraindicated, prior to Cycle 1 Day 1
* Brain magnetic resonance imaging (MRI) during the Screening period unless obtained within 30 days prior to Screening (based on standard clinical care), if they meet either of the following criteria:
1. All participants with TNBC
2. Participants with a history of brain metastases or with neurologic symptoms or signs suspicious for brain metastases.
Exclusion Criteria:
* Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload. Prior treatment with another ADC containing other payloads is allowed.
* Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy to the chest within 3 months of starting study treatment or to other anatomic sites within 14 days of starting study treatment.
* Diagnosis of additional malignancy that required active treatment (including surgery, systemic therapy, and radiation) within 2 years prior to screening, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix.
* Untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis.
* Prior B7-H4 targeted treatment.
* History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver diseases.
* Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could increase the risk of serious adverse events (SAEs) or interfere with per-protocol evaluations, in the judgment of either the Sponsor or the Investigator.
* Clinically significant cardiovascular disease
* Active keratitis (inflammation of the cornea of the eye)
Primary outcome measure(s)
- Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with Emi-Le during the first cycle of treatment (Dose Escalation) — 17 months
Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Emi-Le - Incidence of adverse events (Dose Escalation and Dose Expansion) — 3 years
Assess the safety and tolerability of Emi-Le by determining the number of patients with adverse events from date of first dose to 60 days post last dose - Objective Response Rate (ORR) (Dose Expansion and EMBLEM-1) — approximately 3 years
The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Trial sites (26)
| Facility | City | Region | Status |
|---|---|---|---|
| Mayo Clinic Comprehensive Cancer Center | Phoenix | Arizona | Recruiting |
| UC Irvine Health-Chao Family Comprehensive Cancer Center | Orange | California | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | Recruiting |
| UCLA David Geffen School of Medicine, Division of Hematology/Oncology | Santa Monica | California | Recruiting |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | Recruiting |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | Recruiting |
| Northwestern University | Chicago | Illinois | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | Recruiting |
| Henry Ford Health Hospital | Detroit | Michigan | Recruiting |
| Mayo Clinic - Rochester | Rochester | Minnesota | Recruiting |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | Recruiting |
| New York University Langone Health | New York | New York | Recruiting |
| ICHAN School of Medicine at Mount Sinai | New York | New York | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | Recruiting |
| Stephenson Cancer Center Oklahoma University Health | Oklahoma City | Oklahoma | Recruiting |
| Avera Cancer Institute | Sioux Falls | South Dakota | Recruiting |
| Sarah Cannon Research Institute (SCRI) | Nashville | Tennessee | Recruiting |
| Texas Oncology, P.A. | Dallas | Texas | Recruiting |
| MD Anderson | Houston | Texas | Recruiting |
| Huntsman Cancer Institute | Salt Lake City | Utah | Recruiting |
| NEXT Oncology Virginia | Fairfax | Virginia | Recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | Recruiting |
| Summit Cancer Centers | Spokane | Washington | Recruiting |
More Day One Biopharmaceuticals, Inc. trials in the USA
Other trials for the same condition
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Active, not recruiting
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Active, not recruiting
Study of Monochromatic X-ray Mammography System
Starting soon
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05377996 on ClinicalTrials.gov ↗ ← All trials in the USA